Sino Biopharmaceutical fell 6.49% to HK $4.18 on August 12th, with a total market capitalization of HK $78.6 billion. Sino Biopharmaceutical announced that during the six-month period ended June 30, 2022, due to the lower financial performance of an associate company than in the same period last year, the profits attributable to the group's parent company decreased by as much as 78% to about 1.871 billion yuan compared with the same period last year. During the period, the profit of the attributable associate decreased, but the performance of the group's main business was in line with expectations, and the performance grew steadily compared with the same period last year.